Si-Bone Inc
$ 14.71
-4.11%
04 Mar - close price
- Market Cap 677,496,000 USD
- Current Price $ 14.71
- High / Low $ 15.40 / 14.71
- Stock P/E N/A
- Book Value 4.07
- EPS -0.44
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.11 %
- 52 Week High 21.89
- 52 Week Low 12.49
About
SI-BONE, Inc., a medical device company, develops implantable devices used in the surgical treatment of the sacropelvic anatomy in the United States and internationally. The company is headquartered in Santa Clara, California.
Analyst Target Price
$25.60
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-23 | 2025-11-10 | 2025-08-05 | 2025-05-05 | 2025-02-24 | 2024-11-12 | 2024-08-05 | 2024-05-06 | 2024-02-26 | 2023-11-06 | 2023-08-07 | 2023-05-01 |
| Reported EPS | -0.04 | -0.11 | -0.14 | -0.15 | -0.11 | -0.16 | -0.22 | -0.27 | -0.27 | -0.25 | -0.3 | -0.32 |
| Estimated EPS | -0.1243 | -0.17 | -0.18 | -0.2175 | -0.1343 | -0.24 | -0.28 | -0.31 | -0.28 | -0.34 | -0.4 | -0.41 |
| Surprise | 0.0843 | 0.06 | 0.04 | 0.0675 | 0.0243 | 0.08 | 0.06 | 0.04 | 0.01 | 0.09 | 0.1 | 0.09 |
| Surprise Percentage | 67.8198% | 35.2941% | 22.2222% | 31.0345% | 18.0938% | 33.3333% | 21.4286% | 12.9032% | 3.5714% | 26.4706% | 25% | 21.9512% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.1485 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SIBN
2026-03-04 16:52:36
This article provides an earnings analysis and prediction for SIBN, detailing past quarterly results, future forecasts, and stock price reactions to earnings reports. It highlights analyst estimates for 2026/Q1, which include projected revenue of $52.69M and an EPS of -$0.15, and discusses how earnings forecast revisions correlate with stock price movements. The article also touches on SIBN's recent Q4 2025 earnings call, emphasizing strong growth prospects despite minor financial misses.
2026-03-03 14:51:39
This article provides a detailed financial overview of Si-Bone (SIBN), including its income statement, balance sheet, cash flow statement, and key financial ratios through fiscal year 2025. It highlights the company's strong revenue growth, conservative leverage, and comfortable liquidity, but also points out low profitability, negative free cash flow, and low earnings quality. The analysis includes a Piotroski F-Score, an earnings quality assessment, and an interest coverage ratio to evaluate Si-Bone's overall financial health.
2026-02-27 05:52:30
Smith+Nephew has announced a distribution agreement with SI-BONE for their iFuse TORQ portfolio, which offers solutions for percutaneous pelvic fracture fixation and SI joint fusion. This partnership aims to expand Smith+Nephew's offerings in trauma procedures and leverage SI-BONE's innovative technology, including the iFuse TORQ TNT device with FDA Breakthrough Device Designation and Medicare NTAP eligibility. The collaboration is expected to enhance access to differentiated solutions and improve patient outcomes through increased surgeon engagement.
2026-02-26 15:00:00
Spartan Medical Inc., a Service-Disabled Veteran-Owned Small Business, has partnered with SI-BONE, Inc., a leader in sacroiliac (SI) joint solutions, to provide advanced, ultra-minimally invasive treatment options for Veterans and wounded warriors with SI joint dysfunction. This collaboration aims to address the significant gap in long-term solutions for SI joint pain within VA and DoD facilities. The partnership will make SI-BONE’s iFuse INTRA X® procedure accessible to more patients through Spartan Medical's contract-ready programs and logistics support.
2026-02-25 14:53:00
SI-BONE (SIBN) reported Q4 2025 revenue of US$56.4 million and a narrowed basic EPS loss of US$0.04, finishing FY 2025 with US$200.9 million in revenue and a US$0.44 TTM EPS loss. The company has shown shrinking losses over the past five years, with TTM net losses decreasing from US$37.4 million to US$18.9 million, which bulls interpret as a positive long-term trend despite analysts not expecting profitability within the next three years. Its valuation metrics include a P/S ratio of 3.3x, compared to a peer average of 4.1x and an industry average of 3.0x, alongside an analyst price target of US$25.60.
2026-02-25 12:53:00
SI-BONE, Inc. (NASDAQ:SIBN) reported strong Q4 and full-year 2025 results, with record annual worldwide revenue of nearly $201 million and positive adjusted EBITDA for the full year. The company launched a new product, INTRA Ti, and announced a strategic partnership with Smith & Nephew to expand its trauma market reach. Management provided an outlook for 2026 expecting worldwide revenue of $228.5 million to $232.5 million, emphasizing a back-half weighted growth driven by new product launches and expanded market penetration.
